MedPath

Gemcitabine

These highlights do not include all the information needed to use GEMCITABINE FOR INJECTION safely and effectively. See full prescribing information for GEMCITABINE FOR INJECTION. GEMCITABINE for injection, for intravenous use Initial U.S. Approval: 1996

Approved
Approval ID

d16907e7-a8c8-4039-ace4-cf4e24ba68c0

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Aug 9, 2023

Manufacturers
FDA

Hospira, Inc.

DUNS: 141588017

Products 2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

GEMCITABINE

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code0409-0186
Application NumberANDA078339
Product Classification
M
Marketing Category
C73584
G
Generic Name
GEMCITABINE
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateOctober 21, 2019
FDA Product Classification

INGREDIENTS (5)

GEMCITABINE HYDROCHLORIDEActive
Quantity: 38 mg in 1 mL
Code: U347PV74IL
Classification: ACTIM
MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT
SODIUM ACETATEInactive
Code: 4550K0SC9B
Classification: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT

GEMCITABINE

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code0409-0185
Application NumberANDA078339
Product Classification
M
Marketing Category
C73584
G
Generic Name
GEMCITABINE
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateOctober 21, 2019
FDA Product Classification

INGREDIENTS (5)

GEMCITABINE HYDROCHLORIDEActive
Quantity: 38 mg in 1 mL
Code: U347PV74IL
Classification: ACTIM
MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT
SODIUM ACETATEInactive
Code: 4550K0SC9B
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT

Drug Labeling Information

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LOINC: 51945-4Updated: 10/21/2019

PRINCIPAL DISPLAY PANEL - 1 g Vial Carton

VIAL

Hospira

1 x 1 g Vial
NDC 0409-0186-01

Sterile
Rx only

Gemcitabine
for Injection, USP

1 g/Vial

(lyophilized)

For Intravenous Use Only
DO NOT REFRIGERATE
Single-Dose Vial

Caution: Cytotoxic Agent

PRINCIPAL DISPLAY PANEL - 1 g Vial Carton

INDICATIONS & USAGE SECTION

LOINC: 34067-9Updated: 10/21/2019

1 INDICATIONS AND USAGE

1.1 Ovarian Cancer

Gemcitabine in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.

1.2 Breast Cancer

Gemcitabine in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.

1.3 Non-Small Cell Lung Cancer

Gemcitabine in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC).

1.4 Pancreatic Cancer

Gemcitabine is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine is indicated for patients previously treated with fluorouracil.

Key Highlight

Gemcitabine is a nucleoside metabolic inhibitor indicated:

in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. (1.1)

in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. (1.2)

in combination with cisplatin, for the treatment of non-small cell lung cancer. (1.3)

as a single agent for the treatment of pancreatic cancer. (1.4)

WARNINGS AND PRECAUTIONS SECTION

LOINC: 43685-7Updated: 10/21/2019

5 WARNINGS AND PRECAUTIONS

5.1 Schedule-Dependent Toxicity

In clinical trials evaluating the maximum tolerated dose of gemcitabine, prolongation of the infusion time beyond 60 minutes or more frequent than weekly dosing resulted in an increased incidence of clinically significant hypotension, severe flu-like symptoms, myelosuppression, and asthenia. The half-life of gemcitabine is influenced by the length of the infusion [see Clinical Pharmacology (12.3)]. Refer to the recommended gemcitabine dosage [see Dosage and Administration (2.1, 2.2, 2.3, 2.4)].

5.2 Myelosuppression

Myelosuppression manifested by neutropenia, thrombocytopenia, and anemia occurs with gemcitabine as a single agent and the risks are increased when gemcitabine is combined with other cytotoxic drugs. In clinical trials, Grade 3–4 neutropenia, anemia, and thrombocytopenia occurred in 25%, 8%, and 5%, respectively of the 979 patients who received single agent gemcitabine. The frequencies of Grade 3–4 neutropenia, anemia, and thrombocytopenia varied from 48% to 71%, 8% to 28%, and 5% to 55%, respectively, in patients receiving gemcitabine in combination with another drug [see Adverse Reactions (6.1)].

Prior to each dose of gemcitabine, obtain a complete blood count (CBC) with a differential and a platelet count. Modify the dosage as recommended [see Dosage and Administration (2.1, 2.2, 2.3, 2.4)].

5.3 Pulmonary Toxicity and Respiratory Failure

Pulmonary toxicity, including interstitial pneumonitis, pulmonary fibrosis, pulmonary edema, and adult respiratory distress syndrome (ARDS), has been reported. In some cases, these pulmonary events can lead to fatal respiratory failure despite the discontinuation of therapy. The onset of pulmonary symptoms may occur up to 2 weeks after the last dose of gemcitabine [see Adverse Reactions (6.1, 6.2)].

Permanently discontinue gemcitabine in patients who develop unexplained dyspnea, with or without bronchospasm, or evidence of severe pulmonary toxicity.

5.4 Hemolytic Uremic Syndrome

Hemolytic uremic syndrome (HUS), including fatalities from renal failure or the requirement for dialysis, can occur with gemcitabine. In clinical trials, HUS occurred in 0.25% of 2,429 patients. Most fatal cases of renal failure were due to HUS [see Adverse Reactions (6.1)]. Serious cases of thrombotic microangiopathy other than HUS have been reported with gemcitabine for injection [see Adverse Reactions (6.2)].

Assess renal function prior to initiation of gemcitabine and periodically during treatment. Consider the diagnosis of HUS in patients who develop anemia with evidence of microangiopathic hemolysis; increased bilirubin or LDH; reticulocytosis; severe thrombocytopenia; or renal failure (increased serum creatinine or BUN). Permanently discontinue gemcitabine in patients with HUS or severe renal impairment. Renal failure may not be reversible even with the discontinuation of therapy.

5.5 Hepatic Toxicity

Drug-induced liver injury, including liver failure and death, has been reported in patients receiving gemcitabine alone or with other potentially hepatotoxic drugs [see Adverse Reactions (6.1, 6.2)]. Administration of gemcitabine in patients with concurrent liver metastases or a pre-existing medical history of hepatitis, alcoholism, or liver cirrhosis can lead to exacerbation of the underlying hepatic insufficiency. Assess hepatic function prior to initiation of gemcitabine and periodically during treatment. Permanently discontinue gemcitabine in patients who develop severe hepatic toxicity.

5.6 Embryo-Fetal Toxicity

Based on animal data and its mechanism of action, gemcitabine can cause fetal harm when administered to a pregnant woman. Gemcitabine was teratogenic, embryotoxic, and fetotoxic in mice and rabbits.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with gemcitabine and for 6 months after the final dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with gemcitabine and for 3 months following the final dose [see Use in Specific Populations (8.1, 8.3)].

5.7 Exacerbation of Radiation Therapy Toxicity

Gemcitabine is not recommended for use in combination with radiation therapy.

Concurrent (given together or ≤7 days apart)

Life-threatening mucositis, especially esophagitis and pneumonitis occurred in a trial in which gemcitabine was administered at a dose of 1,000 mg/m2 to patients with non-small cell lung cancer for up to 6 consecutive weeks concurrently with thoracic radiation.

Non-concurrent (given >7 days apart)

Excessive toxicity has not been observed when gemcitabine is administered more than 7 days before or after radiation. Radiation recall has been reported in patients who received gemcitabine after prior radiation.

5.8 Capillary Leak Syndrome

Capillary leak syndrome (CLS) with severe consequences has been reported in patients receiving gemcitabine as a single agent or in combination with other chemotherapeutic agents [see Adverse Reactions (6.2)]. Permanently discontinue gemcitabine if CLS develops during therapy.

5.9 Posterior Reversible Encephalopathy Syndrome

Posterior reversible encephalopathy syndrome (PRES) has been reported in patients receiving gemcitabine as a single agent or in combination with other chemotherapeutic agents [see Adverse Reactions (6.2)]. PRES can present with headache, seizure, lethargy, hypertension, confusion, blindness, and other visual and neurologic disturbances. Confirm the diagnosis of PRES with magnetic resonance imaging (MRI). Permanently discontinue gemcitabine if PRES develops during therapy.

Key Highlight

Schedule-Dependent Toxicity: Increased toxicity with infusion time greater than 60 minutes or dosing more frequently than once weekly. (5.1)

Myelosuppression: Monitor for myelosuppression prior to each cycle and reduce or withhold dose for severe myelosuppression. (5.2, 5.7)

Pulmonary Toxicity and Respiratory Failure: Discontinue gemcitabine for injection for unexplained dyspnea or other evidence of severe pulmonary toxicity. (5.3)

Hemolytic Uremic Syndrome (HUS): Monitor renal function prior to initiation and during treatment. Discontinue gemcitabine for injection for HUS or severe renal impairment. (5.4)

Hepatic Toxicity: Monitor hepatic function prior to initiation and during treatment. Discontinue gemcitabine for injection for severe hepatic toxicity. (5.5)

Embryo-Fetal Toxicity: Can cause fetal harm. Advise females and males of reproductive potential to use effective contraception. (5.6, 8.1)

Exacerbation of Radiation Therapy Toxicity: May cause severe and life-threatening toxicity when administered during or within 7 days of radiation therapy. (5.7)

Capillary Leak Syndrome: Discontinue gemcitabine for injection. (5.8)

Posterior Reversible Encephalopathy Syndrome (PRES): Discontinue gemcitabine for injection. (5.9)

ADVERSE REACTIONS SECTION

LOINC: 34084-4Updated: 10/21/2019

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

Hypersensitivity [see Contraindications (4)]

Schedule-Dependent Toxicity [see Warnings and Precautions (5.1)]

Myelosuppression [see Warnings and Precautions (5.2)]

Pulmonary Toxicity and Respiratory Failure [see Warnings and Precautions (5.3)]

Hemolytic Uremic Syndrome [see Warnings and Precautions (5.4)]

Hepatic Toxicity [see Warnings and Precautions (5.5)]

Exacerbation of Radiation Therapy Toxicity [see Warnings and Precautions (5.7)]

Capillary Leak Syndrome [see Warnings and Precautions (5.8)]

Posterior Reversible Encephalopathy Syndrome [see Warnings and Precautions (5.9)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Single Agent

The data described below reflect exposure to gemcitabine as a single agent administered at doses between 800 mg/m2 to 1,250 mg/m2 intravenously over 30 minutes once weekly in 979 patients with various malignancies. The most common (≥20%) adverse reactions of single agent gemcitabine are nausea/vomiting, anemia, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), neutropenia, increased alkaline phosphatase, proteinuria, fever, hematuria, rash, thrombocytopenia, dyspnea, and edema. The most common (≥5%) Grade 3 or 4 adverse reactions were neutropenia, nausea/vomiting, increased ALT, increased alkaline phosphatase, anemia, increased AST, and thrombocytopenia. Approximately 10% of the 979 patients discontinued gemcitabine due to adverse reactions. Adverse reactions resulting in discontinuation of gemcitabine in 2% of 979 patients were cardiovascular adverse reactions (myocardial infarction, cerebrovascular accident, arrhythmia, and hypertension) and adverse reactions resulting in discontinuation of gemcitabine in <1% of 979 patients were anemia, thrombocytopenia, hepatic dysfunction, renal dysfunction, nausea/vomiting, fever, rash, dyspnea, hemorrhage, infection, stomatitis, somnolence, flu-like syndrome, and edema.

Tables 5 and 6 present the incidence of selected adverse reactions and laboratory abnormalities reported in patients with various malignancies receiving single agent gemcitabine across 5 clinical trials. Additional clinically significant adverse reactions are provided following Table 6.

Table 5: Selected Adverse Reactions Occurring in ≥10% of Patients Receiving Single Agent Gemcitabine*

Adverse Reactions

Gemcitabine

All Grades
(%)

Grade 3
(%)

Grade 4
(%)

  • Grade based on criteria from the World Health Organization (WHO). †

    For approximately 60% of patients, non-laboratory adverse reactions were graded only if assessed to be possibly drug-related. ‡

    N=699-974; all patients with laboratory or non-laboratory data.

Nausea and Vomiting

69

13

1

Fever

41

2

0

Rash

30

<1

0

Dyspnea

23

3

<1

Diarrhea

19

1

0

Hemorrhage

17

<1

<1

Infection

16

1

<1

Alopecia

15

<1

0

Stomatitis

11

<1

0

Somnolence

11

<1

<1

Paresthesias

10

<1

0

Table 6: Selected Laboratory Abnormalities Occurring in Patients Receiving Single Agent Gemcitabine*

Laboratory Abnormality

Gemcitabine

All Grades
(%)

Grade 3
(%)

Grade 4
(%)

  • Grade based on criteria from the WHO. †

    Regardless of causality. ‡

    N=699-974; all patients with laboratory or non-laboratory data.

Hematologic

Anemia

68

7

1

Neutropenia

63

19

6

Thrombocytopenia

24

4

1

Hepatic

Increased ALT

68

8

2

Increased AST

67

6

2

Increased Alkaline Phosphatase

55

7

2

Hyperbilirubinemia

13

2

<1

Renal

Proteinuria

45

<1

0

Hematuria

35

<1

0

Increased BUN

16

0

0

Increased Creatinine

8

<1

0

Additional adverse reactions include the following:

Transfusion requirements: Red blood cell transfusions (19%); platelet transfusions (<1%)

Edema: Edema (13%), peripheral edema (20%), generalized edema (<1%)

Flu-like symptoms: Fever, asthenia, anorexia, headache, cough, chills, myalgia, asthenia insomnia, rhinitis, sweating and/or malaise (19%)

Infection: Sepsis (<1%)

Extravasation: Injection-site reactions (4%)

Allergic: Bronchospasm (<2%); anaphylactoid reactions

Ovarian Cancer

Tables 7 and 8 present the incidence of selected adverse reactions and laboratory abnormalities, occurring in ≥10% of gemcitabine-treated patients and at a higher incidence in the gemcitabine with carboplatin arm, reported in a randomized trial (Study 1) of gemcitabine with carboplatin (n=175) compared to carboplatin alone (n=174) for the second-line treatment of ovarian cancer in women with disease that had relapsed more than 6 months following first- line platinum-based chemotherapy [see Clinical Studies (14.1)]. Additional clinically significant adverse reactions, occurring in <10% of patients, are provided following Table 8.

The proportion of patients with dose adjustments for carboplatin (1.8% versus 3.8%), doses of carboplatin omitted (0.2% versus 0) and discontinuing treatment for adverse reactions (11% versus 10%), were similar between arms. Dose adjustment for gemcitabine occurred in 10% of patients and gemcitabine dose was omitted in 14% of patients in the gemcitabine/carboplatin arm.

Table 7: Adverse Reactions Occurring in >10% of Patients Receiving Gemcitabine with Carboplatin and at Higher Incidence than in Patients Receiving Single Agent Carboplatin [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3–4)] in Study 1*

Adverse Reactions

Gemcitabine/Carboplatin
(N=175)

Carboplatin
(N=174)

All Grades
(%)

Grade 3
(%)

Grade 4
(%)

All Grades
(%)

Grade 3
(%)

Grade 4
(%)

  • Grade based on National Cancer Institute CTC Version 2.0. †

    Regardless of causality.

Nausea

69

6

0

61

3

0

Alopecia

49

0

0

17

0

0

Vomiting

46

6

0

36

2

<1

Constipation

42

6

1

37

3

0

Fatigue

40

3

<1

32

5

0

Diarrhea

25

3

0

14

<1

0

Stomatitis/Pharyngitis

22

<1

0

13

0

0

Table 8: Laboratory Abnormalities Occurring in Patients Receiving Gemcitabine with Carboplatin and at Higher Incidence than in Patients Receiving Single Agent Carboplatin [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3–4)] in Study 1*

Laboratory Abnormality

Gemcitabine/Carboplatin
(N=175)

Carboplatin
(N=174)

All Grades
(%)

Grade 3
(%)

Grade 4
(%)

All Grades
(%)

Grade 3
(%)

Grade 4
(%)

  • Grade based on National Cancer Institute CTC Version 2.0. †

    Regardless of causality. ‡

    Percent of patients receiving transfusions. Transfusions are not CTC-graded events. Blood transfusions included both packed red blood cells and whole blood.

Hematologic

Neutropenia

90

42

29

58

11

1

Anemia

86

22

6

75

9

2

Thrombocytopenia

78

30

5

57

10

1

RBC Transfusions‡

38

15

Platelet Transfusions‡

9

3

Hematopoietic growth factors were administered more frequently in the gemcitabine-containing arm: leukocyte growth factor (24% and 10%) and erythropoiesis-stimulating agent (7% and 3.9%).

The following clinically relevant Grade 3 and 4 adverse reactions occurred more frequently in the gemcitabine with carboplatin arm: dyspnea (3.4% versus 2.9%), febrile neutropenia (1.1% versus 0), hemorrhagic event (2.3% versus 1.1%), motor neuropathy (1.1% versus 0.6%), and rash/desquamation (0.6% versus 0).

Breast Cancer

Tables 9 and 10 present the incidence of selected adverse reactions and laboratory abnormalities, occurring in ≥10% of gemcitabine-treated patients and at a higher incidence in the gemcitabine with paclitaxel arm, reported in a randomized trial (Study 2) of gemcitabine with paclitaxel (n=262) compared to paclitaxel alone (n=259) for the first-line treatment of metastatic breast cancer (MBC) in women who received anthracycline-containing chemotherapy in the adjuvant/neoadjuvant setting or for whom anthracyclines were contraindicated [see Clinical Studies (14.2)]. Additional clinically significant adverse reactions, occurring in <10% of patients, are provided following Table 10.

The requirement for dose reduction of paclitaxel were higher for patients in the gemcitabine/paclitaxel arm (5% versus 2%). The number of paclitaxel doses omitted (<1%), the proportion of patients discontinuing treatment for adverse reactions (7% versus 5%) and the number of treatment-related deaths (1 patient in each arm) were similar between the two arms.

Table 9: Selected Adverse Reactions Occurring in Patients Receiving Gemcitabine with Paclitaxel and at Higher Incidence than in Patients Receiving Single Agent Paclitaxel [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3–4)] in Study 2*

Adverse Reactions

Gemcitabine/Paclitaxel
(N=262)

Paclitaxel
(N=259)

All Grades
(%)

Grade 3
(%)

Grade 4
(%)

All Grades
(%)

Grade 3
(%)

Grade 4
(%)

  • Grade based on National Cancer Institute CTC Version 2.0. †

    Non-laboratory events were graded only if assessed to be possibly drug-related.

Alopecia

90

14

4

92

19

3

Neuropathy-Sensory

64

5

<1

58

3

0

Nausea

50

1

0

31

2

0

Fatigue

40

6

<1

28

1

<1

Vomiting

29

2

0

15

2

0

Diarrhea

20

3

0

13

2

0

Anorexia

17

0

0

12

<1

0

Neuropathy-Motor

15

2

<1

10

<1

0

Stomatitis/Pharyngitis

13

1

<1

8

<1

0

Fever

13

<1

0

3

0

0

Rash/Desquamation

11

<1

<1

5

0

0

Febrile Neutropenia

6

5

<1

2

1

0

Table 10: Selected Laboratory Abnormalities Occurring in >10% of Patients Receiving Gemcitabine with Paclitaxel and at a Higher Incidence than Patients Receiving Single Agent Paclitaxel [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3–4)] in Study 2*

Laboratory Abnormality

Gemcitabine/Paclitaxel
(N=262)

Paclitaxel
(N=259)

All Grades
(%)

Grade 3
(%)

Grade 4
(%)

All Grades
(%)

Grade 3
(%)

Grade 4
(%)

  • Grade based on National Cancer Institute CTC Version 2.0. †

    Regardless of causality.

Hematologic

Anemia

69

6

1

51

3

<1

Neutropenia

69

31

17

31

4

7

Thrombocytopenia

26

5

<1

7

<1

<1

Hepatobiliary

Increased ALT

18

5

<1

6

<1

0

Increased AST

16

2

0

5

<1

0

Clinically relevant Grade 3 or 4 dyspnea occurred with a higher incidence in the gemcitabine with paclitaxel arm compared with the paclitaxel arm (1.9% versus 0).

Non-Small Cell Lung Cancer

Tables 11 and 12 present the incidence of selected adverse reactions and laboratory abnormalities occurring in ≥10% of gemcitabine-treated patients and at a higher incidence in the gemcitabine with cisplatin arm, reported in a randomized trial (Study 3) of gemcitabine with cisplatin (n=260) administered in 28-day cycles as compared to cisplatin alone (n=262) in patients receiving first-line treatment for locally advanced or metastatic NSCLC [see Clinical Studies (14.3)].

Patients randomized to gemcitabine with cisplatin received a median of 4 cycles of treatment and those randomized to cisplatin alone received a median of 2 cycles of treatment. In this trial, the requirement for dose adjustments (>90% versus 16%), discontinuation of treatment for adverse reactions (15% versus 8%), and the proportion of patients hospitalized (36% versus 23%) were all higher for patients receiving gemcitabine with cisplatin compared to those receiving cisplatin alone. The incidence of febrile neutropenia (3% versus<1%), sepsis (4% versus 1%), Grade 3 cardiac dysrhythmias (3% versus <1%) were all higher in the gemcitabine with cisplatin arm compared to the cisplatin alone arm.

The two-drug combination was more myelosuppressive with 4 (1.5%) possibly treatment-related deaths, including 3 resulting from myelosuppression with infection and one case of renal failure associated with pancytopenia and infection. No deaths due to treatment were reported on the cisplatin arm.

Table 11: Selected Adverse Reactions Occurring in ≥10% of Patients Receiving Gemcitabine with Cisplatin and at Higher Incidence than in Patients Receiving Single Agent Cisplatin [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3–4)] in Study 3*

Adverse Reactions

Gemcitabine/Cisplatin

Cisplatin§

All Grades
(%)

Grade 3
(%)

Grade 4
(%)

All Grades
(%)

Grade 3
(%)

Grade 4
(%)

  • Grade based on National Cancer Institute Common Toxicity Criteria (CTC). †

    Non-laboratory events were graded only if assessed to be possibly drug-related. ‡

    N=217–253; all gemcitabine/cisplatin patients with laboratory or non-laboratory data. §

    N=213–248; all cisplatin patients with laboratory or non-laboratory data.

Nausea

93

25

2

87

20

<1

Vomiting

78

11

12

71

10

9

Alopecia

53

1

0

33

0

0

Neuro Motor

35

12

0

15

3

0

Diarrhea

24

2

2

13

0

0

Neuro Sensory

23

1

0

18

1

0

Infection

18

3

2

12

1

0

Fever

16

0

0

5

0

0

Neuro Cortical

16

3

1

9

1

0

Neuro Mood

16

1

0

10

1

0

Local

15

0

0

6

0

0

Neuro Headache

14

0

0

7

0

0

Stomatitis

14

1

0

5

0

0

Hemorrhage

14

1

0

4

0

0

Hypotension

12

1

0

7

1

0

Rash

11

0

0

3

0

0

Table 12: Selected Laboratory Abnormalities Occurring in >10% of Patients Receiving Gemcitabine with Cisplatin and at Higher Incidence than in Patients Receiving Single Agent Cisplatin [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3–4)] in Study 3*

Laboratory Abnormality

Gemcitabine/Cisplatin

Cisplatin§

All Grades
(%)

Grade 3
(%)

Grade 4
(%)

All Grades
(%)

Grade 3
(%)

Grade 4
(%)

  • Grade based on National Cancer Institute CTC. †

    Regardless of causality. ‡

    N=217–253; all gemcitabine/cisplatin patients with laboratory or non-laboratory data §

    N=213–248; all cisplatin patients with laboratory or non-laboratory data ¶

    Percent of patients receiving transfusions. Percent transfusions are not CTC-graded events.

Hematologic

Anemia

89

22

3

67

6

1

Thrombocytopenia

85

25

25

13

3

1

Neutropenia

79

22

35

20

3

1

Lymphopenia

75

25

18

51

12

5

RBC Transfusions¶

39

13

Platelet Transfusions¶

21

<1

Hepatic

Increased Transaminases

22

2

1

10

1

0

Increased Alkaline Phosphatase

19

1

0

13

0

0

Renal

Increased Creatinine

38

4

<1

31

2

<1

Proteinuria

23

0

0

18

0

0

Hematuria

15

0

0

13

0

0

Other Laboratory

Hyperglycemia

30

4

0

23

3

0

Hypomagnesemia

30

4

3

17

2

0

Hypocalcemia

18

2

0

7

0

<1

Tables 13 and 14 present the incidence of selected adverse reactions and laboratory abnormalities occurring in ≥10% of gemcitabine-treated patients and at a higher incidence in the gemcitabine with cisplatin arm, reported in a randomized trial (Study 4) of gemcitabine with cisplatin (n=69) administered in 21-day cycles as compared to etoposide with cisplatin (n=66) in patients receiving first-line treatment for locally advanced or metastatic non-small cell lung cancer NSCLC [see Clinical Studies (14.3)]. Additional clinically significant adverse reactions are provided following Table 14.

Patients in the gemcitabine/cisplatin (GC) arm received a median of 5 cycles and those in the etoposide/cisplatin (EC) arm received a median of 4 cycles. The majority of patients receiving more than one cycle of treatment required dose adjustments; 81% in the GC arm and 68% in the EC arm. The incidence of hospitalizations for adverse reactions was 22% in the GC arm and 27% in the EC arm. The proportion of patients who discontinued treatment for adverse reactions was higher in the GC arm (14% versus 8%). The proportion of patients who were hospitalized for febrile neutropenia was lower in the GC arm (7% versus 12%). There was one death attributed to treatment, a patient with febrile neutropenia and renal failure, which occurred in the GC arm.

Table 13: Selected Adverse Reactions in Patients Receiving Gemcitabine with Cisplatin in Study 4*

Adverse Reactions

Gemcitabine/Cisplatin

Etoposide/Cisplatin§

All Grades
(%)

Grade 3
(%)

Grade 4
(%)

All Grades
(%)

Grade 3
(%)

Grade 4
(%)

  • Grade based on criteria from the WHO. †

    Non-laboratory events were graded only if assessed to be possibly drug-related. Pain data were not collected. ‡

    N=67–69; all gemcitabine/cisplatin patients with laboratory or non-laboratory data. §

    N=57–63; all etoposide/cisplatin patients with laboratory or non-laboratory data. ¶

    Flu-like syndrome and edema were not graded.

Nausea and Vomiting

96

35

4

86

19

7

Alopecia

77

13

0

92

51

0

Paresthesias

38

0

0

16

2

0

Infection

28

3

1

21

8

0

Stomatitis

20

4

0

18

2

0

Diarrhea

14

1

1

13

0

2

Edema¶

12

2

Rash

10

0

0

3

0

0

Hemorrhage

9

0

3

3

0

3

Fever

6

0

0

3

0

0

Somnolence

3

0

0

3

2

0

Flu-like Syndrome¶

3

0

Dyspnea

1

0

1

3

0

0

Table 14: Selected Laboratory Abnormalities Occurring in Patients Receiving Gemcitabine with Cisplatin in Study 4*

Laboratory Abnormality

Gemcitabine/Cisplatin

Etoposide/Cisplatin§

All Grades
(%)

Grade 3
(%)

Grade 4
(%)

All Grades
(%)

Grade 3
(%)

Grade 4
(%)

  • Grade based on criteria from the WHO. †

    Regardless of causality. ‡

    N=67–69; all gemcitabine/cisplatin patients with laboratory or non-laboratory data. §

    N=57–63; all etoposide/cisplatin patients with laboratory or non-laboratory data. ¶

    WHO grading scale not applicable to proportion of patients with transfusions.

Hematologic

Anemia

88

22

0

77

13

2

Neutropenia

88

36

28

87

20

56

Thrombocytopenia

81

39

16

45

8

5

RBC Transfusions‡

29

21

Platelet Transfusions¶

3

8

Hepatic

Increased Alkaline Phosphatase

16

0

0

11

0

0

Increased ALT

6

0

0

12

0

0

Increased AST

3

0

0

11

0

0

Renal

Hematuria

22

0

0

10

0

0

Proteinuria

12

0

0

5

0

0

Increased BUN

6

0

0

4

0

0

Increased Creatinine

2

0

0

2

0

0

6.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of gemcitabine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

 Blood and lymphatic system: Thrombotic microangiopathy (TMA)

 Cardiovascular: Congestive heart failure, myocardial infarction, arrhythmias, supraventricular arrhythmias

 Vascular: Peripheral vasculitis, gangrene, capillary leak syndrome

 Skin: Cellulitis, pseudocellulitis, severe skin reactions, including desquamation and bullous skin eruptions

 Hepatic: Hepatic failure, hepatic veno-occlusive disease

 Pulmonary: Interstitial pneumonitis, pulmonary fibrosis, pulmonary edema, adult respiratory distress syndrome (ARDS), pulmonary eosinophilia

 Nervous System: Posterior reversible encephalopathy syndrome (PRES)
Key Highlight

The most common adverse reactions for the single-agent (≥20%) are nausea/vomiting, anemia, increased aspartate aminotransferase (AST), increased alanine aminotransferase (ALT), neutropenia, increased alkaline phosphatase, proteinuria, fever, hematuria, rash, thrombocytopenia, dyspnea, and edema. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Gemcitabine - FDA Drug Approval Details